



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 100 508 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**INID code(s) 54**
- (48) Corrigendum issued on:  
**07.01.2004 Bulletin 2004/02**
- (45) Date of publication and mention  
of the grant of the patent:  
**27.08.2003 Bulletin 2003/35**
- (21) Application number: **99923960.1**
- (22) Date of filing: **08.06.1999**
- (51) Int Cl.7: **A61K 31/55**, A61K 31/495,  
A61K 31/435  
// (A61K31/55, 31:34),  
(A61K31/495, 31:34),  
(A61K31/435, 31:34,  
A61P25:20)
- (86) International application number:  
**PCT/JP1999/003057**
- (87) International publication number:  
**WO 1999/063977 (16.12.1999 Gazette 1999/50)**

(54) **PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROtizOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS**

PHARMATZEUTISCHE KOMBINATION MIT EINER TRIZYCLISCHEN VERBINDUNG UND MINDESTENS EINER VON ZOLPIDEM, ZOPICLONE UND BROtizOLAM, ZUR BEHANDLUNG ODER VERHINDERUNG VON SCHLAFSTÖRUNGEN

COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSE TRICYCLIQUE ET AU MOIN UN PARMi ZOLPIDEM, ZOPICLONE ET BROtizOLAM DESTINEE A TRAITER OU PREVENIR LES TROUBLES DU SOMMEIL

- |   |  |
|---|--|
| <p>(84) Designated Contracting States:<br/><b>AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</b></p> <p>(30) Priority: <b>09.06.1998 JP 16027098</b></p> <p>(43) Date of publication of application:<br/><b>23.05.2001 Bulletin 2001/21</b></p> <p>(73) Proprietor: <b>Takeda Chemical Industries, Ltd.</b><br/><b>Osaka-shi, Osaka 541-0045 (JP)</b></p> <p>(72) Inventors:<br/>• <b>OHKAWA, Shigenori</b><br/><b>Takatsuki-shi, Osaka 569-1121 (JP)</b><br/>• <b>MIYAMOTO, Masaomi</b><br/><b>Takarazuka-shi, Hyogo 665-0841 (JP)</b></p> | <p>(74) Representative:<br/><b>Kaiser, Jürgen, Dr.rer.nat.Dipl.-Chem. et al</b><br/><b>Winter, Brandl, Fürniss, Hübner,</b><br/><b>Röss, Kaiser, Polte</b><br/><b>Partnerschaft</b><br/><b>Patent- und Rechtsanwaltskanzlei</b><br/><b>Alois-Steinecker-Strasse 22</b><br/><b>85354 Freising (DE)</b></p> <p>(56) References cited:<br/><b>EP-A- 0 513 702</b> <b>WO-A-97/32871</b></p> <ul style="list-style-type: none"><li>• <b>PIERGIES ET AL: "The effect of co-administration of zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics" INTERNATIONAL JOURNAL OF CLINICAL PHARMACOL. THER., vol. 34, no. 4, 1996, pages 178-183, XP002120169</b></li><li>• <b>FERINI-STRAMBI L ET AL: "Effect of melatonin on sleep microstructure: preliminary result in healthy subjects." SLEEP, (1993 DEC) 16 (8) 744-7. , XP002120170</b></li></ul> |
|---|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 100 508 B8